CAM Group Holding A S purchased a new stake in Glaukos Corp. (NYSE:GKOS) during the second quarter, Holdings Channel reports. The institutional investor purchased 75,000 shares of the company’s stock, valued at approximately $2,187,000.
Other hedge funds also recently added to or reduced their stakes in the company. BP PLC bought a new stake in Glaukos Corp. during the second quarter valued at about $426,000. Essex Investment Management Co. LLC bought a new stake in Glaukos Corp. during the second quarter valued at about $614,000. Strs Ohio increased its stake in Glaukos Corp. by 409.1% in the second quarter. Strs Ohio now owns 11,200 shares of the company’s stock valued at $326,000 after buying an additional 9,000 shares during the period. Hamilton Lane Advisors LLC increased its stake in Glaukos Corp. by 68.2% in the second quarter. Hamilton Lane Advisors LLC now owns 67,666 shares of the company’s stock valued at $1,648,000 after buying an additional 27,446 shares during the period. Finally, Iguana Healthcare Management LLC bought a new stake in Glaukos Corp. during the first quarter valued at about $2,042,000. Institutional investors own 72.11% of the company’s stock.
Glaukos Corp. (NYSE:GKOS) traded down 2.13% during trading on Wednesday, reaching $34.52. The company’s stock had a trading volume of 324,233 shares. The firm’s 50-day moving average is $35.74 and its 200-day moving average is $28.97. The stock’s market cap is $1.14 billion. Glaukos Corp. has a 52-week low of $14.25 and a 52-week high of $39.82.
Glaukos Corp. (NYSE:GKOS) last released its quarterly earnings results on Monday, August 1st. The company reported $0.06 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.10. Glaukos Corp. had a negative return on equity of 1.14% and a negative net margin of 1.23%. The firm had revenue of $28.60 million for the quarter, compared to the consensus estimate of $24.45 million. During the same quarter last year, the business posted ($1.30) EPS. The company’s revenue for the quarter was up 60.7% on a year-over-year basis. Equities research analysts forecast that Glaukos Corp. will post $0.11 EPS for the current year.
GKOS has been the subject of several research analyst reports. Zacks Investment Research raised Glaukos Corp. from a “hold” rating to a “strong-buy” rating and set a $44.00 price objective for the company in a research report on Wednesday, October 5th. Stifel Nicolaus reissued a “hold” rating on shares of Glaukos Corp. in a research report on Tuesday, September 27th. Piper Jaffray Cos. boosted their price objective on Glaukos Corp. to $42.00 in a research report on Tuesday, August 2nd. Cantor Fitzgerald reissued a “buy” rating and set a $41.00 price objective on shares of Glaukos Corp. in a research report on Sunday, September 25th. Finally, Roth Capital boosted their price objective on Glaukos Corp. from $36.50 to $41.00 and gave the stock a “buy” rating in a research report on Tuesday, August 2nd. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $39.20.
In other news, CFO Richard L. Harrison sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, July 27th. The stock was sold at an average price of $35.01, for a total value of $350,100.00. Following the completion of the transaction, the chief financial officer now owns 11,388 shares in the company, valued at approximately $398,693.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jonathan Silverstein sold 292,938 shares of the firm’s stock in a transaction dated Friday, August 12th. The shares were sold at an average price of $33.69, for a total value of $9,869,081.22. The disclosure for this sale can be found here. 36.80% of the stock is owned by insiders.
About Glaukos Corp.
Glaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent, an MIGS device measuring approximately one millimeter long and approximately 0.33 millimeter wide.
Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corp. (NYSE:GKOS).
Receive News & Ratings for Glaukos Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corp. and related companies with MarketBeat.com's FREE daily email newsletter.